Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
Christopher Koh(National Institutes of Health), Theo Heller(National Institutes of Health), Gitanjali Subramanya(Loyola University Medical Center), Mark A. Winters(Stanford Medicine), David E. Kleiner, Scott J. Cotler(Loyola University Medical Center), Ramazan Idılman(Ankara University), Peter A. Pinto(National Cancer Institute), Harel Dahari(Loyola University Medical Center), Rachel Bishop(National Eye Institute), Stewart Cooper(California Pacific Medical Center), Onur Keskın(Ankara University), Vanessa Haynes–Williams(National Institute of Diabetes and Digestive and Kidney Diseases), Xiongce Zhao(National Institute of Diabetes and Digestive and Kidney Diseases), Susan L. Uprichard(Loyola University Medical Center), Cihan Yurdaydın(Ankara University), Jeffrey S. Glenn(Stanford Medicine), Ma Ai Thanda Han(National Institute of Diabetes and Digestive and Kidney Diseases), E.F. Wolff(National Institutes of Health), Laëtitia Canini(Loyola University Medical Center)
Cited by 262
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889